Skip to main content
. 2015 Oct 19;6(41):43508–43528. doi: 10.18632/oncotarget.6180

Figure 4. Archazolid A induces cell death in human patient derived xenograft (PDX) samples.

Figure 4

A. Viability of leukemic PDX samples with/without treatment with Archazolid A (Arch) for 72h at indicated concentrations is shown. B. PI exclusion staining of leukemic PDX samples with/without treatment with Archazolid A (Arch) for 48h at indicated concentrations is shown. Upper panels display dot plots and histograms of PDX leukemic cells from one respective patient (PDX ALL-169). Dead cells are stained by PI and are marked in red. Live cells without PI staining are displayed in green. Lower panels show apoptosis rate of PDX leukemic cells treated with Archazolid A (Arch) at indicated concentrations. C. The specific apoptosis rate determined by Annexin V/PI staining of PDX cells after treatments with Archazolid A (Arch) at indicated concentrations for 48h is shown. D. Immunoblots of PDX samples treated with Archazolid A (10 nM, 48h) for procaspase-3 (procasp-3) are shown. Ponceau staining indicates equal loading. E. Archazolid A does not induce cell death in non-tumor primary human PBMCs. Apoptosis rate determined by Annexin V/PI staining and of non-tumor primary human PBMCs (FACS analysis with gating for lymphocytes) of two different donors treated with Archazolid A (Arch) at indicated concentrations for 48h is shown.